Capsaicin 8% dermal patch in clinical practice: an expert opinion

References

• Blair HA. Capsaicin 8% dermal patch: a review in peripheral neuropathic pain. Drugs. 2018;78(14):1489–1500.
   PubMed Web of Science ®Google Scholar
• Zilliox LA. Neuropathic pain. Continuum. 2017;23(2):512–532.
   PubMedGoogle Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics: qutenza 179 mg cutaneous patch. 2017. cited 2018 Sep 10. Available from: http://www.ema.europa.eu.
   Google Scholar
• Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
   PubMed Web of Science ®Google Scholar
• O’Neill J, Brock C, Olesen AE, et al. Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev. 2012;64(4):939–971.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. CHMP assessment report for Qutenza. 2009. Available from: cited 2018 Sep 10 http://www.ema.europa.eu.
   Google Scholar
• Peppin JF, Majors K, Webster LR, et al. Tolerability of NGX- 4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res. 2011;4:385–392.
   PubMedGoogle Scholar
• Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manage. 2017;53(3):614–629.
   PubMed Web of Science ®Google Scholar
• Mick G, Baron R, Finnerup NB, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2(1):71–77.
   PubMedGoogle Scholar
• Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(Suppl 1):35–42.
   PubMed Web of Science ®Google Scholar
• Pickering G, Martin E, Tiberghien F, et al. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709–2718.
   PubMed Web of Science ®Google Scholar
• Price TJ, Gold MS. From mechanism to cure: renewing the goal to eliminate the disease of pain. Pain Med. 2018;19(8):1525–1549.
   PubMed Web of Science ®Google Scholar
• Usoskin D, Furlan A, Islam S, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci. 2015;18(1):145–153.
   PubMed Web of Science ®Google Scholar
• Häring M, Zeisel A, Hochgerner H, et al. Neuronal atlas of the dorsal horn defines its architecture and links sensory input to transcriptional cell types. Nat Neurosci. 2018;21(6):869–880.
   PubMed Web of Science ®Google Scholar
• Nau C, Leipold E Voltage-gated sodium channels and pain. cited 20 June 2019. Available at: https://www.degruyter.com/view/j/nf.2017.23.issue-3/nf-2017-A017/nf-2017-A017.xml.
   Google Scholar
• Dib-Hajj SD, Waxman SG. Diversity of composition and function of sodium channels in peripheral sensory neurons. Pain. 2015;156(12):2406–2407.
   PubMed Web of Science ®Google Scholar
• Hu T, Liu N, Lv M, et al. Lidocaine inhibits HCN currents in rat spinal substantia gelatinosa neurons. Anesth Analg. 2016;122(4):1048–1059.
   PubMed Web of Science ®Google Scholar
• Dickenson AH, Patel R. Sense and sensibility-logical approaches to profiling in animal models. Pain. 2018;159(7):1426–1428.
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155(11):2263–2273.
   PubMed Web of Science ®Google Scholar
• Vay L, Gu C, McNaughton PA. The thermo-TRP ion channel family: properties and therapeutic implications. Br J Pharmacol. 2012;165(4):787–801.
   PubMed Web of Science ®Google Scholar
• Kremeyer B, Lopera F, Cox JJ, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron. 2010;66(5):671–680.
   PubMed Web of Science ®Google Scholar
• Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11(12):823–836.
   PubMed Web of Science ®Google Scholar
• Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain. 1992;51(2):175–194.
   PubMed Web of Science ®Google Scholar
• Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol. 2013;74(5):630–636.
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113e1123.
   Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162e173.
   Web of Science ®Google Scholar
• Gilron I. Treatment of neuropathic pain: antiepileptic and antidepressant drugs educational objectives. In: Sommer CL, Raja SN, editors. Pain 2014: refresher courses, 15th world congress on pain. Washington, DC, USA: IASP Press; 2014. p. 225e237.
   Google Scholar
• Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2015;15:47e57.
   Web of Science ®Google Scholar
• Torrance N, Ferguson JA, Afolabi E, et al. Neuropathic pain in the community: more under-treated than refractory? Pain. 2013;154:690e699.
   Web of Science ®Google Scholar
• Allegri M, Baron R, Hans G, et al. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32:377–384.
   PubMed Web of Science ®Google Scholar
• Martini C, Yassen A, Olofsen E, et al. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res. 2012;5:51–59.
   PubMedGoogle Scholar
• Bley KR. TRPV1 agonist approaches for pain management. In: Gomtsyan A, Faltynek CR, editors. Vanilloid receptor TRPV1 in drug discovery: targeting pain and other pathological disorders. New York: Wiley; 2010. p. 325–347.
   Google Scholar
• Babbar S, Marier J-F, Mouksassi M-S, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502–510.
   PubMed Web of Science ®Google Scholar
• Cruccu G, Nurmikko TJ, Ernault E, et al. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur J Pain. 2018;22(4):700–706.
   PubMed Web of Science ®Google Scholar
• Haanpaa M, Cruccu G, Nurmikko TJ, et al., Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 20(2): 316–328. 2016. .
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, doubleblind, placebo-controlled study. J Pain. 2017;18(1):42–53.
   PubMed Web of Science ®Google Scholar
• Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther. 2013;10(1):5.
   PubMedGoogle Scholar
• Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126–133.
   PubMed Web of Science ®Google Scholar
• Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a highconcentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99–109.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–2313.
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a highconcentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106–1112.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(251):1–14.
   PubMedGoogle Scholar
• Perrot S, Ortega E, Vinik EJ, et al. Efficacy, quality of life and treatment satisfaction with capsaicin 8% patch versus standard of care in painful diabetic peripheral neuropathy [abstract no. 1067]. Diabetologia. 2015;58(Suppl.1):S514.
   Google Scholar
• Simpson DM, Brown S, Tobias JK, et al., NGX-4010 C107 Study Group. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014;30(2):134–142.
   PubMed Web of Science ®Google Scholar
• Backonja MM, Malan TP, Vanhove GF. NGX-4010, a highconcentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11:600–608.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39(6):1053–1064.
   PubMed Web of Science ®Google Scholar
• Churruca I, Miro P, Suñer R, et al. Capsaicin (8%) patch in urological patients with neuropathic pain due to scar [abstract]. Presented at: 9th World Congress of the World Institute of Pain. 2018 Aug 24.
   Google Scholar
• Tenreiro Pinto J, Pereira FC, Loureiro MC, et al. Efficacy analysis of capsaicin 8% patch in neuropathic peripheral pain treatment. Pharmacology. 2018;101(5–6):290–297.
   PubMed Web of Science ®Google Scholar
• Churruca I. Capsaicin 8% patch in urological patients with neuropathic pain [abstract no. WIP16-0048]. Pain Pract. 2016;16(Suppl.1):48.
   Google Scholar
• Privitera R, Birch R, Sinisi M, et al. Capsaicin 8% patch treatment for amputation stump and phantom limb pain: a clinical and functional MRI study. J Pain Res. 2017;10:1623–1634.
   PubMed Web of Science ®Google Scholar
• Bardo-Brouard P, Luizard C, Valeyrie-Allanore L, et al. High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case series. Curr Med Res Opin. 2018;34(5):887–891.
   PubMed Web of Science ®Google Scholar
• Mankowski C, Poole CD, Ernault E, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017;17(80):1–11.
   PubMedGoogle Scholar
• Levesque A, Riant T, Labat -J-J, et al. Use of high-concentration capsaicin patch for the treatment of pelvic pain: observational study of 60 inpatients. Pain Physician. 2017;20(1):E161–7.
   PubMed Web of Science ®Google Scholar
• Perrot S, Lantéri-Minet M. Patients’ global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Epub 2019 Mar 18 Eur J Pain. 2019;236:1117–1128.
   PubMed Web of Science ®Google Scholar
• Hansson P, Jensen TS, Kvarstein G, et al. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Eur J Pain. 2018;22(5):941–950.
   PubMed Web of Science ®Google Scholar
• Gustorff B, Poole C, Kloimstein H, et al. Treatment of neuropathic pain with the capsaicin 8% patch: quantitative sensory testing (QST) in a prospective observational study identifies potential predictors of response to capsaicin 8% patch treatment. Scand J Pain. 2017;4(3):138–145.
   Google Scholar
• Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol. 2017;34(162):1–5.
   PubMedGoogle Scholar
• Aitken E, McColl G, Kingsmore D. The role of Qutenza® (topical capsaicin 8%) in treating neuropathic pain from critical ischemia in patients with end-stage renal disease: an observational cohort study. Pain Med. 2017;18(2):330–340.
   PubMed Web of Science ®Google Scholar
• Zis P, Bernali N, Argira E, et al. Effectiveness and impact of capsaicin 8% patch on quality of life in patients with lumbosacral pain: an open-label study. Pain Physician. 2016;19(7):E1049–53.
   PubMed Web of Science ®Google Scholar
• Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP-study. Eur J Pain. 2014;18(5):671–679.
   PubMed Web of Science ®Google Scholar
• Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–683.
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Perrot S. QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France. Curr Med Res Opin. 2019;35(3):417–426.
   PubMed Web of Science ®Google Scholar
• Galvez R, Navez ML, Moyle G, et al. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin J Pain. 2017;33(10):921–931.
   PubMed Web of Science ®Google Scholar
• Rorbaek M, Ventzel L, Gottrup H. Treatment with topical capsaicin: experience from a pain clinic [abstract no. F34]. Scand J Pain. 2017;3(3):197.
   Google Scholar
• Marec CLE, Berard J, Queneuille I, et al. Improvement of chemotherapy induced neuropathy (CIN) in cancer patients using capsaicin 8% patch [abstract no. e14031]. J Clin Oncol. 2016;34(15Suppl):e14031–e14031.
   Google Scholar
• Reeves K, Tilak D, Putt O. Is an 8% capsicum patch (Qutenza) an alternative to traditional neuropathic pain management following breast surgery [abstract no. 138460]? Reg Anesth Pain Med. 2016;41(5Suppl.):e116.
   Google Scholar
• van Nooten F, Treur M, Pantiri K, et al., Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 39(4): 787–803. 2017. .
   PubMed Web of Science ®Google Scholar
• Mankowski C, Patel S, Trueman D, et al. Cost-effectiveness of capsaicin 8% patch compared with pregabalin for the treatment of patients with peripheral neuropathic pain in Scotland. PLoS One. 2016;11(3):e0150973.
   PubMed Web of Science ®Google Scholar